Default company panoramic image
Logo

Quantitative Insights, Inc.

We are transforming Cancer Diagnosis and Therapy through machine learning driven, outcomes correlated, computer decision support.

  • Stage Full Product Ready
  • Industry Medical Devices and Equipment
  • Location Chicago, IL, USA
  • Currency USD
  • Founded March 2010
  • Employees 2
  • Incorporation Type C-corp
  • Website quantinsights.com

Company Summary

Quantitative Insights, Inc. (QI) provides the world’s first and only FDA cleared artificial intelligence based computer-aided diagnosis system, shown to increase both the efficiency and accuracy of cancer diagnosis. Based on technology developed at and licensed from the University of Chicago, QuantX improves radiologist's confidence while significantly reducing costs, thereby providing benefit to clinicians, practice administrators and patients.

Team

  • Default avatar
    R. Keith Tipton
    President and CEO

    Keith is a medical device industry veteran with expertise in computer-aided detection, diagnostic imaging and cancer therapy devices. He is an accomplished R&D and business management executive with 14 years at Philips Healthcare prior to joining QI, the last three years as R&D head of the incubator Women’s Health business. He has start-up experience which led to IPO and M&A experience nurturing small companies to success.

  • Default avatar
    Robert Tomek
    Chief Technology Officer

    Rob has spent the past 8 years working closely with Dr. Giger developing novel algorithms to enhance diagnostic efficiency from complex medical images. He focuses on intuitive user interfaces, display technologies, and analysis algorithms, while exploring how clinicians interact with these applications. This work led to a variety of patents, many of which are licensed by Quantitative Insights. Rob is the principle creator of the QuantX product.

  • Default avatar
    Maryellen Giger, PhD
    Scientific Advisor

    Dr. Giger’s career spans more than 25 years of research in computer-aided diagnosis (CAD) and quantitative image analysis in breast cancer, lung cancer, and bone diseases leading to over 150 peer-reviewed publications and 39 patents. She is one of the inventors of the Mammography CAD solution in wide clinical use today. The patented technology upon which QuantX is based was developed in Dr. Giger’s labs.

  • Default avatar
    Gillian Newstead, M.D.
    Medical Advisor

    Dr. Newstead is past Chief of Breast Imaging at the University of Chicago. A recognized global expert in multimodal assessment and quantitative analysis of breast cancer, she currently conducts translational research into novel methods of analysis of breast MRI, ultrasound and mammographic images. She also trains Radiologists in all facets of multi-modality and MR imaging of the breast. Dr. Newstead is chair of QI’s Medical Advisory Board.

Advisors

  • Default avatar
    Jim Jerue, Horwood Marcus & Berk Chartered
    Lawyer
    Unconfirmed
    Default avatar
    Josh Harris, NDH Group
    Accountant
    Unconfirmed

Previous Investors

  • Default avatar
    Ron Landes, Landes Bioscience, Austin, TX
    Unconfirmed
    Default avatar
    Laszlo Tabar, M.D., Professor Emeritus, Uppsala, Sweden
    Unconfirmed
    Default avatar
    Bob Wang, CAD Industry Pioneer, San Francisco, CA
    Unconfirmed